Welcome to our dedicated page for Bitwise MARA Option Income Strategy ETF SEC filings (Ticker: IMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bitwise MARA Option Income Strategy ETF's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bitwise MARA Option Income Strategy ETF's regulatory disclosures and financial reporting.
On June 24, 2025, Enliven Therapeutics, Inc. (Nasdaq: ELVN) convened its Annual Meeting of Stockholders. Three Class II directors were re-elected by wide margins: Rahul D. Ballal, Ph.D. (36,870,420 for / 460,073 withheld), Jake Bauer, M.B.A. (37,250,826 for / 79,667 withheld) and Andrew Phillips, Ph.D. (31,957,928 for / 5,372,565 withheld). Broker non-votes on these items totaled 8,099,804.
Shareholders also ratified Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 with 45,392,647 for, 2,435 against and 35,215 abstentions; no broker non-votes were recorded on this item.
No additional proposals were presented. The 8-K therefore reflects routine corporate-governance matters and discloses no new operational or financial information likely to affect the Company’s valuation in the near term.
Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, reported selling 12,500 shares of common stock on June 20, 2025, at a weighted average price of $21.3966 per share (ranging from $21.1228 to $22.0249), resulting in an approximate transaction value of $267,458.
Key details of the transaction:
- The sale was executed according to a Rule 10b5-1 trading plan established on November 15, 2024
- Following the transaction, Lyssikatos maintains indirect beneficial ownership of 965,188 shares through The Lyssikatos Revocable Trust 12/15/2011, where he serves as trustee
- The transaction was reported via Form 4 filing on June 24, 2025
Enliven Therapeutics (NASDAQ:ELVN) filed a routine Form 4 reporting that President & CEO Samuel Kintz sold a total of 12,500 common shares on June 17 2025 under a pre-arranged Rule 10b5-1 trading plan.
The shares were sold in two tranches at weighted-average prices of $22.08 and $22.75, generating roughly $275 thousand in gross proceeds. Following the transactions, Kintz, through The Kintz & Egan Trust, continues to beneficially own approximately 952,892 shares, representing a reduction of about 1.3 % of his indirect holdings.
No derivative securities were involved, and there were no purchases disclosed. Because the disposition is both under 5 % of total holdings and under $1 million in value, it is generally viewed as a non-material routine insider sale rather than a signal of strategic change.
FAQ
What is the current stock price of Bitwise MARA Option Income Strategy ETF (IMRA)?
What is the market cap of Bitwise MARA Option Income Strategy ETF (IMRA)?
